Connect study teams, research sites and participants with practical organize participant progress and study milestones suited to the scale and complexity of clinical research in Delhi.
Delhi/NCR is one of India’s largest clinical-research markets. The source register snapshot lists 332 studies with New Delhi sites. AIIMS New Delhi operates a Clinical Research Unit and documents clinical-trial and translational-research activity. The source also identifies Sir Ganga Ram Hospital, Rajiv Gandhi Cancer Institute, Max Super Speciality Hospital, CIDP India and Tupalin Research as part of the research ecosystem. Clinical research activity changes over time, so this page uses a September 2026 snapshot as market context rather than a permanent study count.
The wider Delhi clinical-research ecosystem includes AIIMS New Delhi, Sir Ganga Ram Hospital, Rajiv Gandhi Cancer Institute, Max Super Speciality Hospital, CIDP India and Tupalin Research. These organizations are cited as examples of the local research environment and are not eTrialTrack customers unless a documented customer relationship exists.
For organizations operating in Delhi, the relevant technology question is not simply whether a digital platform is available, but whether it can support the operational requirements of the study. eTrialTrack Participant Tracker can be evaluated for workflows involving high-volume tertiary research, oncology and complex studies, participant tracking, electronic data capture and remote participant workflows. The product is designed to provide organize participant progress and study milestones through enrollment status, visits, follow-up, milestones, tasks and participant-level operational visibility. The exact configuration should be determined by protocol requirements, organizational procedures, user roles, integrations and implementation scope.
Organizations in Delhi can evaluate eTrialTrack Participant Tracker when they need a practical workflow that can be configured around their study rather than a generic process. Relevant product capabilities include Enrollment Status; Participant Milestones; Visit Scheduling; Follow-Up Tracking; Task Visibility; Participant-Level Progress; Study-Level Visibility; Connected Product Workflows. Where appropriate, the module can connect with other eTrialTrack capabilities to create a more coherent participant, site and data workflow.
A typical discussion for a Delhi study can begin with study requirements, participant and site workflows, data responsibilities, user roles, integrations, implementation timelines and support expectations. From there, the relevant eTrialTrack capabilities can be configured and evaluated against the study requirements.
AIIMS New Delhi, Sir Ganga Ram Hospital, Rajiv Gandhi Cancer Institute, Max Super Speciality Hospital, CIDP India and Tupalin Research. These names describe the broader market context only and should not be presented as customers, partners or users of eTrialTrack without documented evidence.
eTrialTrack Participant Tracker is a technology capability, not a substitute for the approved protocol, investigator responsibilities, ethics requirements, applicable regulations, quality procedures or clinical judgment. Product suitability should be assessed against the specific study and documented requirements.
For research teams in Delhi, the Participant Tracker module fits specific roles and study situations — here's who it serves, what it supports, and when to adopt it.
eTrialTrack Participant Tracker provides an organized participant-level operational view across screening, enrollment, visits, follow-up and study milestones. The focus is operational visibility rather than clinical decision-making.
Yes — eTrialTrack is FDA 21 CFR Part 11, ICH-GCP, HIPAA and GDPR compliant, with complete audit trails and e-signatures accepted by Indian (CDSCO) and global regulators.
Most teams go live in 2-4 weeks, including configuration, validation support and team training in IST.
Absolutely — book a 30-minute guided walkthrough and we will tailor it to your Delhi study setup and protocols.